Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.

Main Article Content

Matteo Dragani
Jessica Petiti
Giovanna Rege-Cambrin
Enrico Gottardi
Filomena Daraio
Giovanni Caocci
Chiara Aguzzi
Elena Crisà
Giacomo Andreani
Francesca Caciolli
Carmen Fava
(*) Corresponding Author:

Abstract

Discontinuation of tyrosine kinase inhibitors (TKI) is the main goal today in the field of Philadelphia positive chronic myeloid leukemia (Ph + CML) and the criteria to attempt the interruption of therapy are well defined and rely on the possibility to regularly monitor the BCR-ABL1 transcript. Patients harboring atypical transcripts are automatically excluded from protocols due to the absence of a standardized method of quantification of their minimal residual disease (MRD). We report here the outcome of 6 patients with atypical transcripts with a long follow up whose MRD was followed in three cases with digital PCR during their treatment free remission (TFR).


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Most read articles by the same author(s)